Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders

Leukemia

Volumn 26, Issue 12, 2012, Pages 2447-2454

  Visconte, V ^a   Makishima, H ^a   MacIejewski, J P ^a   Tiu, R V ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

MDS; mutations; spliceosome

Indexed keywords

ANTINEOPLASTIC AGENT; E 7107; FR 901464; MEAYAMYCIN; MEMBRANE PROTEIN; PLADIENOLIDE; SERINE ARGINE RICH SPLICING FACTOR 2; SPLICEOSTATIN; SPLICING FACTOR 1; SPLICING FACTOR 3A SUBUNIT 1; SUDEMYCIN; TRANSCRIPTION FACTOR; U2 SMALL NUCLEAR RNA AUXILLARY FACTOR 1; U2 SMALL NUCLEAR RNA AUXILLARY FACTOR 2; UNCLASSIFIED DRUG; ZRSRS2 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW DEPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HEMATOLOGIC DISEASE; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; JUVENILE MYELOMONOCYTIC LEUKEMIA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PATHOGENESIS; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; SPLICEOSOME;

HEMATOLOGIC DISEASES; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RNA SPLICING; SPLICEOSOMES;

EID: 84871236747     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.130     Document Type: Review

References (60)

1. Will CL, Schneider C, MacMillan AM, Katopodis NF, Neubauer G, Wilm M et al. A novel U2 and U11/U12 snRNP protein that associates with the pre-mRNA branch site. EMBO J 2001; 20: 4536-4546.
2. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009; 10: 741-754.
3. Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol 2010; 220: 152-163.
4. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
5. Marz M, Kirsten T, Stadler PF. Evolution of spliceosomal snRNA genes in metazoan animals. J Mol Evol 2008; 67: 594-607.
6. Corden JL, Patturajan MA. CTD function linking transcription to splicing. Trends Biochem Sci 1997; 22: 413-416.
7. Valadkhan S. snRNAs as the catalysts of pre-mRNA splicing. Curr Opin Chem Biol 2005; 9: 603-608.
8. Sheth N, Roca X, Hastings ML, Roeder T, Krainer AR, Sachidanandam R. Comprehensive splice-site analysis using comparative genomics. Nucleic Acids Res 2006; 34: 3955-3967.
9. Yokoi A, Kotake Y, Takahashi K, Kadowaki T, Matsumoto Y, Minoshima Y et al. Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J 2011; 278: 4870-4880.
10. Lopez AJ. Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. Annu Rev Genet 1998; 32: 279-305.
11. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542-545.
12. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
13. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
14. Ghosh G, Adams JA. Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J 2011; 278: 587-597.
15. Moorhead GB, Trinkle-Mulcahy L, Ulke-Lemee A. Emerging roles of nuclear protein phosphatases. Nat Rev Mol Cell Biol 2007; 8: 234-244.
16. Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R. Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 2005; 579: 1900-1903.
17. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2011; 44: 53-57.
18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
19. Cazzola M, Invernizzi R. Ring sideroblasts and sideroblastic anemias. Haematolo-gica 2011; 96: 789-792.
20. Ducamp S, Kannengiesser C, Touati M, Garcon L, Guerci-Bresler A, Guichard JF et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat 2011; 32: 590-597.
21. Steensma DP, Hecksel KA, Porcher JC, Lasho TL. Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed side-roblasts). Leuk Res 2007; 31: 623-628.
22. Sheftel AD, Richardson DR, Prchal J, Ponka P. Mitochondrial iron metabolism and sideroblastic anemia. Acta Haematol 2009; 122: 120-133.
23. Halfdanarson TR, Kumar N, Li CY, Phyliky RL, Hogan WJ. Hematological manifestations of copper deficiency: a retrospective review. Eur J Haematol 2008; 80: 523-531.
24. Latvala J, Parkkila S, Melkko J, Niemela O. Acetaldehyde adducts in blood and bone marrow of patients with ethanol-induced erythrocyte abnormalities. Mol Med 2001; 7: 401-405.
25. Napier I, Ponka P, Richardson DR. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 2005; 105: 1867-1874.
26. Isono K, Mizutani-Koseki Y, Komori T, Schmidt-Zachmann MS, Koseki H. Mammalian polycomb-mediated repression of Hox genes requires the essential spli-ceosomal protein Sf3b1. Genes Dev 2005; 19: 536-541.
27. Visconte V, Makishima H, Jankowska A, Traina F, Szpurka H, Rogers HJ et al. Association of SF3B1 with ring sideroblasts in patients, in vivo, and in vitro models of Spliceosomal Dysfuntion. Blood 2011; 118: 457.
28. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011; 118: 6239-6246.
29. Damm F, Thol F, Kosmider O, Kade S, Loffeld P, Dreyfus F et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2011; e-pub ahead of print 8 November 2011; doi:10.1038/leu.2011.321.
30. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119: 569-572.
31. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F et al. Muta-tional spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011; 118: 3932-3941.
32. Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z et al. Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010; 24: 1799-1804.
33. Saunthararajah Y, Maciejewski J. Polycomb segment myeloid malignancies. Blood 2012; 119: 1097-1098.
34. Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 2011; e-pub ahead of print 8 November 2011; doi:10.1038/leu.2011.320.
35. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497-2506.
36. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118: 6904-6908.
37. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011; 44: 47-52.
38. Makishima H, Sakaguchi H, Visconte V, Jerez A, Jankowska AM, Guinta KM et al. Acquired molecular defects in spliceosome machinery: novel pathogenetic pathways in myeloid leukemogenesis. Blood 2011; 118: 271.
39. Traina F, Jankowska AM, Visconte V, Sugimoto Y, Szpurka H, Makishima H et al. Impact of molecular mutations on treatment response to hypomethylating agents in MDS. Blood 2011; 118: 461.
40. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119: 3203-3210.
41. Edmond V, Moysan E, Khochbin S, Matthias P, Brambilla C, Brambilla E et al. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J 2011; 30: 510-523.
42. Nagata Y, Sanada M, Kon A, Yoshida K, Shiraishi Y, Sato-Otsubo A et al. Mutational spectrum analysis of interesting correlation and interrelationship between RNA splicing pathway and commonly targeted genes in myelodysplastic syndrome. Blood 2011; 118: 273.
43. Schnittger S, Meggendorfer M, Kohlmann A, Grossmann V, Yoshida K, Ogawa S et al. SRSF2 is mutated in 47.2% (77/163) of chronic myelomonocytic leukemia (CMML) and prognostically favorable in cases with concomitant RUNX1 mutations. Blood 2011; 118: 274.
44. Xiao R, Sun Y, Ding JH, Lin S, Rose DW, Rosenfeld MG et al. Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Mol Cell Biol 2007; 27: 5393-5402.
45. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
46. Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005; 6: 386-398.
47. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010; 24: 2343-2364.
48. D'Souza I, Poorkaj P, Hong M, Nochlin D, Lee VM, Bird TD et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromo-some 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci USA 1999; 96: 5598-5603.
49. Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20: 589-602.
50. Huntsman MM, Tran BV, Potkin SG, Bunney Jr. WE, Jones EG. Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics. Proc Natl Acad Sci USA 1998; 95: 15066-15071.
51. Vawter MP, Frye MA, Hemperly JJ, VanderPutten DM, Usen N, Doherty P et al. Elevated concentration of N-CAM VASE isoforms in schizophrenia. J Psychiatr Res 2000; 34: 25-34.
52. Silberstein GB, Van Horn K, Strickland P, Roberts Jr. CT, Daniel CW. Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997; 94: 8132-8137.
53. Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 1994; 91: 484-488.
54. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
55. Suzuki S, Kurata M, Abe S, Miyazawa R, Murayama T, Hidaka M et al. Over-expression of MCM2 in myelodysplastic syndromes: association with bone marrow cell apoptosis and peripheral cytopenia. Exp Mol Pathol 2012; 92: 160-166.
56. Jankowska A, Huang Y, Ko M, Pape UJ, Makishima H, Szpurka H et al. Mechanisms of defective hydroxylation of 5-methylcytosine in MDS include pathways other than TET2 and IDH1/2. Blood 2011; 118: 462.
57. Hammond SM, Wood MJ. Genetic therapies for RNA mis-splicing diseases. Trends Genet 2011; 27: 196-205.
58. Rymond B. Targeting the spliceosome. Nat Chem Biol 2007; 3: 533-535.
59. Albert BJ, McPherson PA, O'Brien K, Czaicki NL, Destefino V, Osman S et al. Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol Cancer Ther 2009; 8: 2308-2318.
60. Lagisetti C, Pourpak A, Goronga T, Jiang Q, Cui X, Hyle J et al. Synthetic mRNA splicing modulator compounds with in vivo antitumor activity. J Med Chem 2009; 52: 6979-6990.